CRISPR Therapeutics AG financials
$55.32−1.21%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M | $719.0K | $289.6M | $3.1M | $41.0M | $5.2M |
| Gross profit | $3.5M | $37.3M | $371.2M | $1.2M | $915.0M | $719.0K | $289.6M | $3.1M | $41.0M | $5.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$664.6M | -$466.6M | -$222.5M | -$673.2M | $373.5M | -$354.4M | $46.7M | -$158.9M | -$64.6M | -$68.1M |
| Net income | -$581.6M | -$366.3M | -$153.6M | -$650.2M | $377.7M | -$348.9M | $66.9M | -$165.0M | -$68.4M | -$23.2M |
| Net margin | −16569.8% | −981.5% | −41.4% | −54271.7% | 41.3% | −48520.9% | 23.1% | −5281.1% | −166.7% | −448.8% |
| Diluted EPS | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | $-1.89 |
| EBITDA | -$645.1M | -$447.3M | -$202.7M | -$649.0M | $391.5M | -$345.3M | $51.5M | -$155.4M | -$61.6M | -$67.2M |
| Operating cash flow | -$345.0M | -$142.8M | -$260.4M | -$495.7M | $539.0M | -$238.4M | $56.7M | -$96.2M | -$70.1M | -$52.9M |
| Free cash flow | -$345.9M | -$144.7M | -$269.8M | -$532.9M | $457.3M | -$256.7M | $50.0M | -$99.0M | -$77.9M | -$55.9M |
| Diluted shares | 89.9M | 84.4M | 79.2M | 77.7M | 80.4M | 65.9M | 56.9M | 48.0M | 40.1M | 12.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $347.6M | $298.3M | $389.5M | $211.9M | $923.0M | $1.17B |
| Short-term investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $521.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B |
| Total liabilities | $343.4M | $310.0M | $346.8M | $367.6M | $352.4M | $163.7M |
| Shareholders' equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology